Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | LTK | P29376 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2041519 | 0.71 | MAPT (0.40) | MAPTNOS1KDM4EMEN1KMT2A | |
| SCHEMBL10054248 | 0.71 | HTR2A (0.39) | HTR2AHTR2CMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6196904 | 0.70 | MAPT (0.46) | MAPTNOS1KDM4EMEN1KMT2A | |
| SCHEMBL10054250 | 0.70 | HTR2A (0.41) | HTR2AHTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL4063814 | 0.69 | MAPT (0.41) | MAPTNOS1HTR2AHTR2CKDM4E | |
| SCHEMBL29592501 | 0.69 | MAPT (0.41) | MAPTNOS1HTR2AHTR2CKDM4E | |
| Bromide SCHEMBL29228836 | 0.68 | MAPT (0.40) | MAPTNOS1HTR2AHTR2CKDM4E | |
| SCHEMBL15590643 | 0.67 | MAPT (0.56) | MAPTNOS1KDM4EMEN1KMT2A | |
| SCHEMBL29591329 | 0.67 | MAPT (0.56) | MAPTNOS1KDM4EMEN1KMT2A | |
| SCHEMBL29620425 | 0.67 | MAPT (0.42) | MAPTNOS1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2856528-B1 | METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS | MERCK PATENT GMBH (DE) | 2019-07-03 | — | — | EP | disclosed |
| US-9879177-B2 | Metal complexes comprising condensed heteroaromatic rings | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879177-B2 | Metal complexes comprising condensed heteroaromatic rings | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-20150105843-A1 | METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS | UDC IRELAND LIMITED (IE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105843-A1 | METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS | UDC IRELAND LIMITED (IE) | 2015-04-16 | — | — | US | disclosed |
| WO-2013174471-A1 | METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS | MERCK PATENT GMBH (DE) | 2013-11-28 | — | — | WO | disclosed |
| US-7129257-B1 | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2006-10-31 | — | — | US | disclosed |
| US-7129257-B1 | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2006-10-31 | — | — | US | disclosed |
| US-7129257-B1 | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2006-10-31 | — | — | US | disclosed |
| US-20060069096-A1 | Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma | DANTANARAYANA ANURA P | 2006-03-30 | — | — | US | disclosed |
| US-20060069096-A1 | Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma | DANTANARAYANA ANURA P | 2006-03-30 | — | — | US | disclosed |
| US-20060069096-A1 | Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma | DANTANARAYANA ANURA P | 2006-03-30 | — | — | US | disclosed |
| EP-0990650-B1 | TRICYCLIC PYRROLE OR PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-6245796-B1 | NERVOUS SYSTEM DISORDERS; SEXUAL DISORDERS; SLEEP DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-0990650-A1 | TRICYCLIC PYRROLE OR PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069096-A1 | Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma | PTGIR, PDE3A, TBXA2R | MAPT 2442/4885NOS1 1972/4885HTR2A 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.